Pharmaceutical - Antibiotics and Infectious diseases, GlaxoSmithKline


Popular Filters

Ebola vaccines could be available early 2015, says WHO

Ebola vaccines could be available early 2015, says WHO


The World Health Organization has issued an assessment of the situation regarding two candidate Ebola…

Antibiotics and Infectious diseasesGlaxoSmithKlineGlobalPharmaceuticalResearch

Tamiflu use called into question by UK report

Tamiflu use called into question by UK report


The UK government and health policy decision makers are being called upon to review the guidance on the…

Antibiotics and Infectious diseasesChemistryDavid ToveyGlaxoSmithKlineHealthcareMajorPharmaceuticalRelenzaResearchRocheTamifluThe British Medical JournalUKUK government

GSK’s Synflorix gets additional indication in Europe

GSK’s Synflorix gets additional indication in Europe


The European Commission has granted marketing authorization for an additional indication for UK pharma…

Antibiotics and Infectious diseasesEuropeGlaxoSmithKlinePharmaceuticalRegulationSynflorix

Case study draws attention to innovator brand preferences in Kenya


Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics


UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

GlaxoSmithKline and Abbott to start production in Ukraine


UK pharma giant GlaxoSmithKline (LSE: GSK) and the USA's Abbott (NYSE: ABT) are considering launching…

Anti-viralsAntibiotics and Infectious diseasesEuropeGlaxoSmithKlineIndarPharmaceuticalProductionVaccines

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

US FDA approvals for Signifor, raxibacumab and Iclusig


In a flurry of activity from the US Food and Drug Administration on Friday, the agency - which looks…

Antibiotics and Infectious diseasesAriad PharmaceuticalsGlaxoSmithKlineIclusigNorth AmericaNovartisOncologyPharmaceuticalRare diseasesraxibacumabRegulationSignifor

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Further initiatives from GlaxoSmithKline to help tackle global health challenges; TB deal with Aeras


UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday announced new measures to further advance its commitment…

Antibiotics and Infectious diseasesGlaxoSmithKlineGlobalHealthcarePharmaceuticalResearchVaccines

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor


Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch



Back to top